FDA approves third dose of vaccine for immunocompromised people

The U.S. Food and Drug Administration (FDA) has updated the Emergency Use Authorization

The agency has authorized immunocompromised people to receive a third dose of the vaccine at least 28 days after two doses to further enhance protection.The FDA said the change would affect tens of thousands of people in the country.

“The country has entered the next wave of a pandemicCOVID-19, and the FDA is especially aware that immunocompromised people are at risk of severe illness. After carefully reviewing the available data, the FDA has determined that a third dose of Pfizer-BioNTech or Moderna vaccines could benefit a small vulnerable group, ”said Acting FDA Commissioner Janet Woodcock.

COVID-19 and Myths: Why You Shouldn't Be Afraid of Long-Term Consequences After Vaccination

“As we stated earlier, people whoFully vaccinated, adequately protected, and does not need an additional dose of COVID-19 vaccine. The FDA is actively involved in a scientifically based, rigorous process with our federal partners to consider the need for an additional dose in the future, ”the FDA added.

The FDA is expected to approve the third dose of Moderna and Pfizer / BioNTech mRNA vaccines. They will get permission for the third dose by updating the emergency use documents.

Johnson & Johnson's single-dose COVID-19 vaccine has been excluded from the updates.According to Politico's sources, this is due to the fact that very few immunocompromised people have previously received the Johnson & Johnson vaccine.

Read more

Unknown virus genetic material found in human DNA

NASA's plan to search for life on the satellite of Saturn has been published

Wild ticks will be specially released in Russia for pest control